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Severe Infantile Encephalomyopathy
Caused by a Mutation in COX6B1,
a Nucleus-Encoded Subunit of Cytochrome C Oxidase
Valeria Massa,1,7 Erika Fernandez-Vizarra,1,7 Saad Alshahwan,2 Eman Bakhsh,3 Paola Goffrini,4
Ileana Ferrero,4 Paolo Mereghetti,5 Pio D’Adamo,6 Paolo Gasparini,6 and Massimo Zeviani1,*
Cytochrome c oxidase (COX) deﬁciency, one of the most common respiratory-chain defects in humans, has been associated with
mutations in either mitochondrial DNA genes or nucleus-encoded proteins that are not part in but promote the biogenesis of COX.
Mutations of nucleus-encoded structural subunits were sought for but never found in COX-defective patients, leading to the conjecture
that they may be incompatible with extra-uterine survival. We report a disease-associated mutation in one such subunit, COX6B1.
Nuclear-encoded COX genes should be reconsidered and included in the diagnostic mutational screening of human disorders related
to COX deﬁciency.Introduction
Cytochrome c oxidase (COX, complex IV), the terminal en-
zyme in the mitochondrial respiratory chain, catalyzes the
electron transfer from reduced cytochrome c to molecular
oxygen. This reaction is coupled to the extrusion of protons
from the mitochondrial matrix to the intermembrane
space, forming a proton-based membrane potential that
allowsATP to be synthesized. Inmammals, theCOXmono-
mer is composed of 13 subunits, but the active form of the
enzyme works as a dimer in vivo. Mitochondrial DNA
(mtDNA) encodes the three larger, and most hydrophobic,
subunits, including the two catalyticMT-CO1 andMT-CO2
subunits, aswell as the core structuralMT-CO3 subunit. The
remaining ten smaller subunits, COX4, 5A, B, 6A, B, C, 7A,
B, C, and 8, some of which have also tissue-speciﬁc iso-
forms, are encoded in the nucleus and imported into mito-
chondria.1 Most of the nuclear encoded subunits of COX
have hydrophobic domains spanning the inner mitochon-
drial membrane once.2 However, subunits COX5A,
COX5B, and COX6B are hydrophilic extramembrane pro-
teins, the ﬁrst two facing the matrix, whereas COX6B faces
the intermembrane space. According to the bovine enzyme
structure, COX subunit 6B, a 10 kDa polypeptide, connects
the two COX monomers into the physiological dimeric
form2,3 and is alsobelieved to interactwith cytochromec.4,5
COX deﬁciency (MIM 220110) is one of the most com-
mon respiratory-chain defects in humans, being associated
with different clinical phenotypes and caused by different
genetic abnormalities. The study of COX defects is compli-
cated as the biosynthesis and function of the enzyme
depends on the contribution of both mitochondrial and
nuclear encoded products.The AmMutations in mtDNA-encoded COX genes (MIM
516030, 516040, and 516050) are associated with a range
of phenotypes including pure myopathy, MELAS (MIM
540000), encephalomyopathy, and a motor neuron dis-
ease-like presentation.6 In other cases, COX deﬁciency is
associated with mutations in nuclear-encoded proteins
that do not belong to, but participate in the biogenesis
of, complex IV.7 Mutations in nuclear-encoded COX struc-
tural subunits were searched for but never found.8–11
We studied two siblings belonging to a consanguineous
Arab family originating from the Saudi-Yemeni border,
presenting with a combination of early-onset leukody-
strophic encephalopathy (Figures 1A and 1B), myopathy,
and growth retardation associated with COX deﬁciency
of unknown cause. Linkage analysis followed by sequenc-
ing of candidate genes revealed the presence of a missense
mutation in the COX6B1 gene.
Subjects and Methods
Subjects
Written informed consent was obtained by the parents of the
patients and investigations were carried out according to the
guidelines of the Ethical Committee of the ‘‘Fondazione Istituto
Neurologico Carlo Besta,’’ in agreement with the Italian and Euro-
pean Union law.
The patients, both affected by similar leukodystrophic changes
(Figures 1A and 1B), were the two youngest brothers of a family
composedofﬁve sibs fromthird-degree cousinparents of SaudiAra-
bian origin (Figure 2A). A sister and brother of the patients are alive
and well. A ﬁfth female child died immediately after birth because
of ventilation difﬁculty. The mother had previously had a second
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Figure 2A) was the product of uneventful pregnancy. Birth weight
and height are not known but were reported as abnormally low
and remained below the 3rd percentile ever since. He was a thin
boy, with reduced muscle mass, but the psychomotor milestones
were reached timely and appropriately. At 6 years he was admitted
for the ﬁrst time to the RiyadhMilitary Hospital because of muscle
weakness andpain.During a subsequenthospitalization at 10 years
hewas found to suffer ofmuscleweakness, cognitive deterioration,
and visual loss. The visual evoked potentials were absent, whereas
the brainstempotentials were present and normal. The lower cervi-
cal and upper cervical somatosensory evoked potentials were
reduced in amplitude. An electromyography (EMG) showed signs
of lower and uppermotor neuron involvement. An electroenceph-
alogram (EEG) showed a poorly organized, slow background
rhythm with no photic reaction and no epileptic discharges.
Several brain magnetic resonance imaging (MRI) examinations
showed progressive, diffuse leukodystrophic changes in the cere-
bellum,pyramidal tracts and supratentorialwhitematter,with later
development of whitematter vacuolation from the peritrigonal to-
ward the frontal areas, and ex vacuo dilatation of the lateral ventri-
cles (Figure 1A). The patient died at 10 years by rapidly progressive
neurological deterioration after recurrent generalized convulsions
and severe metabolic acidosis with very high serum lactic acid
levels. The second patient (individual AW, #16 in Figure 2A) had
aclinical course similar to,butmilder than, thatof theelderbrother.
He was born after uneventful pregnancy; birth weight was 2.6 Kg,
head circumference was 33 cm, and height was 47 cm. He was
kept in thenursery because of poor sucking anddifﬁculty in breath-
ing.Thepsychomotordevelopmentwasnormaluntil 6yearsof age,
when he experienced repeated episodes of unsteady gait and visual
disturbances. Presently he is an 8-year-old boywithmild trunk and
limb ataxia, muscle weakness, reduced visual acuity, andmoderate
cognitive deterioration (IQ ¼ 84). The body weight is 19 Kg (90th
centile), height is 110 cm (3rd centile). Laboratory investigation
showed high serum lactate levels (2.6 mM, normal value [n.v.] <
1.8) and cerebrospinal ﬂuid (CSF) (5.1 mM, n.v. < 1.8). EMG
showed predominantly myopathic changes; gas chromatography-
mass spectrometry (GC-MS) analysis of urine was normal. Brain
MRI showed symmetrical, diffuse leukodystrophy with cystic
lesions in the supratentorial areas of the white matter (Figure 1B).
Figure 1. Brain MRI Panel
(A) Patient AK at 9 years of age. Bilateral,
symmetrical signal abnormalities affect the
frontal, parietal, and occipital white mat-
ter, as well as the splenium and the genu
of the corpus callosum. Numerous cystic le-
sions are also present, particularly in the
anterior periventricular regions, with
ex vacuo dilation of the lateral ventricles.
(B) Patient AW at 6 years of age presented
symmetrical white matter hyperintensity
in the periventricular region, with cystic
vacuolation. The splenium of the corpus
callosum is also involved.
Methods
Linkage Analysis
Genome-wide search was performed with
the ABI PRISM Linkage Mapping Set v.2.5
(ABI), characterized by over 375 markers
that deﬁne a 10 cM resolution human index map. Polymerase
chain reactions (PCRs) with ﬂuorescently labeled primers were
run under the conditions suggested by the supplier. An aliquot
of each PCR was run on an ABI PRISM 3130 DNA sequencer,
and results were processed by GENEMAPPER software. Statistical
analysis was performed on the basis of an autosomal-recessive dis-
ease with complete penetrance. The disease-gene frequency was
set to 0.001, and all marker alleles were considered to be equally
frequent. Haplotyping and multipoint parametric analysis were
performed by SimWalk212–14 v.2.91 with Markov chain Monte-
Carlo (MCMC) and simulated annealing algorithms. Files for
SimWalk analysis were prepared with the Mega215 software
version 3.0.
Sequence Analysis
Molecular analysis was performed on genomic DNA extracted
either from muscle or ﬁbroblasts. Overlapping PCR-ampliﬁed
fragments of the four COX6B1 exons were sequenced in a 3100
ABI Prism Automated Sequencer. The presence of the mutated
allele in patients and controls was also assessed by restriction frag-
ment length polymorphism (RFLP) with the restriction enzyme
Fnu4HI and denaturing high-performance liquid chromatography
(DHPLC) analysis of PCR products.
Protein Modeling
Proteinmodeling was carried out on the crystal structure of bovine
COX in fully reduced state (PDB code 2EIJ). The ionic interactions
of the R19 residue were identiﬁed with the online software Protein
Interaction Calculator.
Cell Culture and Media
Cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplied with 10% fetal calf serum at 37C in a 5%
CO2 atmosphere. Fibroblasts from both patients and control
were immortalized by electroporation of the cells with the
pBABE40 plasmid and subsequent selection with 0.5 mg/ml puro-
mycin in the culture medium.16
The full-length human IMAGE complementary DNA (cDNA)
clone for Homo sapiens COX6B1 (accession number BC002478)
was obtained from the RZPD (clone IRAUp969D1010D6) and
was used to generate the cDNA fragment by ampliﬁcation. The
PCR products were cloned into the pcDNA3.2/V5/GW/D-TOPO
vector (Invitrogen). The G/A substitution found in the patients1282 The American Journal of Human Genetics 82, 1281–1289, June 2008
was introduced in the recombinant cDNA by site-directed muta-
genesis with the Quick Change Kit (Stratagene). The recombinant
plasmids encoding the wild-type and mutated COX6B1 cDNAs
were transfected by electroporation into the immortalized ﬁbro-
blast cell lines and underwent antibiotic selection by addition of
G418 (200 mg/ml) to the culture medium to create the stably trans-
fected cell lines.
Biochemical Analysis
Biochemical activity assays of the individual respiratory-chain
complexes in cultured primary and immortalized skin ﬁbroblasts
lysates obtained by treatment with digitonin and in muscle
homogenate were carried out according to.17 Speciﬁcally, measure-
ments of cytochrome c oxidase activity were performed spectro-
photometrically after the decrease of absorbance at 550 nm, be-
cause of oxidation of cytochrome c, during 120 s at 38C.18 The
same experiments were carried out in yeast-isolated mitochondria
at 30C. Enzymatic activity of each complex was normalized to
that of citrate synthase.
Analysis of COX Assembly
Mitochondrial fractions were isolated from immortalized ﬁbro-
blasts andHeLa cells as previously described,19 lysed, and thenelec-
trophoresed through a sodiumdodecyl sulfate (SDS)-Urea-Glycerol
denaturing polyacrylamide gel.20 For the detection of the assem-
bled complex IV in control and patient skin ﬁbroblast and muscle
biopsies, blue-native gel electrophoresis (BNGE) was used. Samples
were obtained from 23 106 cultured ﬁbroblasts or 25mg ofmuscle
biopsy,21 or throughtheuseof isolatedmitochondria from153106
cultured cells,22 with slight modiﬁcations. Twenty microliters of
samplewere loadedand run intoa5%–13%gradientnondenaturat-
ing ﬁrst dimension (1D)-BNGE. For western blot (WB) analysis, the
gels were electroblotted onto polyvinylidene diﬂuoride (PVDF)
ﬁlters and sequentially immunostained with speciﬁc antibodies
againstdifferentCOXsubunits and the30kDa subunit of complex II
(SDH) fornormalizationpurposes. All the antibodiesusedwere com-
mercial and supplied by Molecular Probes (Invitrogen).
Analysis of Yeast Models
Yeast strains used were BY4741 (MATa; his3D1 leu2D0 lys2D0
ura3D0) and its isogenic cox12::kanMX4 mutant (Euroscarf collec-
tion). Cells were cultured in yeast nitrogen base (YNB) medium
(0.67% yeast nitrogen base without amino acids [Difco]) supple-
mented with 1 g/l of drop-out powder containing all amino acids
except those required for plasmid maintenance. Various carbon
sources were added at 2% (w/v). Media were solidiﬁed with 20 g/l
agar. For respiration analysis, cells were grown to late-log phase in
the YNB medium supplemented with 0.5% glucose.
Transformation of yeast strains was obtained by the lithium
acetate method.23 Restriction-enzyme digestions, Escherichia coli
transformation, and plasmid extractions were performed with
standard methods.24 Oxygen uptake rate was measured at 30C
with a Clark electrode in a reaction vessel of 3 ml of air-saturated
respiration buffer (0.1M phthalate–NaOH [pH 5.0]), 10 mM
glucose, starting the reaction with the addition of 20 mg of wet
weight of cells as previously described.25
The S. cerevisiae expression vector pYEX-BX (Clontech) was em-
ployed. The wild-type humanCOX6B1 cDNAwas cloned in EcoRI-
digested pYEX plasmid under the control of CUP1 promoter. The
point mutation corresponding to that found in the patient was
generated with the QuickChange Site Directed Mutagenesis kit
from Stratagene.
RNA Interference and mRNA Analysis and Quantification
The small interfering RNA (siRNA) candidate targets, used to
design the short hairpin RNA (shRNA) oligonucleotides to beThe Amcloned into the expression vectors, aiming at different positions
in the 50 untranslated region (UTR) and 30 UTR of the COX6B1
messenger RNA (mRNA), were calculated with a web-based algo-
rithm. The oligonucleotide pairs were cloned into pSuper.gfp/
neo and pSuperior.puro expression vectors (OligoEngine) accord-
ing to the manufacturer’s instructions. HeLa cells were transiently
transfected by electroporation with the four different constructs
cloned into pSuper.gfp/neo, allowing the evaluation of the
transfection efﬁciency by ﬂuorescence detection of the enhanced
green ﬂuorescent protein (EGFP) expression. The amount of the
COX6B1 mRNA, quantiﬁed 72 hr after transfection, showed that
the constructs expressing the shRNAs corresponding to sequences
1 (COX6B1sh1) and 14 (COX6B1sh14) were the most efﬁcient in
knocking down the expression of the COX6B1 transcript. HeLa
cells stably expressing COX6B1sh1 or COX6B1sh14were obtained
by transfection of the constructs in pSuperior.puro vector and se-
lection of cells by the addition of puromycin (0.25 mg/ml) to the
culture medium. RNA from cultured cells was extracted with the
RNeasy mini kit (QIAGEN). Then, the RNA was retrotranscribed
by random primers in the Cloned AMV First-Strand cDNA Synthe-
sis Kit (Invitrogen). The amount of COX6B1mRNAwas quantiﬁed
by real-time PCR with the Power SYBR Green PCR Master Mix
(Applied Biosystems).
Statistical Analysis
Differences in COX activity between the different cell lines was
assessed with the unpaired, two-tail Student’s t test. The tests
and calculations were performed with the Statview 5.0 software.
Results
Morphological and Biochemical Studies
The histochemical reaction to COX was diffusely low in
a skeletal muscle biopsy from patient AK (Figure 2B). The
COX speciﬁc activity normalized to that of Citrate
Synthase (CS, and index of mitochondrial mass, was dras-
tically reduced in muscle homogenates from both patients
(approximately 20% of the normal mean), and it was
mildly but signiﬁcantly reduced also in primary and im-
mortalized cultured ﬁbroblasts (approximately 50% from
both patients); the activities of other respiratory complexes
were normal in both tissues (Tables 1 and 2).
Linkage Analysis and Mutation Screening
Genome-wide linkage analysis allowed us to identify
a unique locus of continuous homozygosity between
recombinant DNA microsatellite markers D19S226 and
D19S902, with amultipoint location score of 2.9 (Figure 2A
and Figure S1 available online). Three genes encoding COX
structural subunits are contained within this region: the
ubiquitously expressed COX6B1 and COX7A1 and the
testis-speciﬁc COX6B2 isoform. We found no change in
COX7A1 and COX6B2 genes, but both probands carried
a homozygous c.221G/A substitution in exon 2 of
COX6B1, predicting a p.R19H amino acid change (numer-
ation according to the mature protein in which the ﬁrst
M is eliminated). A pathogenic role for this mutation was
suggested by its segregation with the disease according to
a recessive trait, its absence in 100 Arab and 1000 Italian
control alleles, and the absolute evolutionary conservationerican Journal of Human Genetics 82, 1281–1289, June 2008 1283
Figure 2. Genetic, Clinical, and Biochemical Analysis
(A) Family pedigree and haplotype analysis of the COX6B1 locus. Patients (#15, patient AK; #16, patient AW) are indicated by black
symbols.
(B) COX histoenzymatic staining of muscle biopsy. The reaction is diffusely low in the muscle from patient AW, compared with an
age-matched control (inset).
(C) Electropherogram of the c.221G/A mutation in exon 2 of the COX6B1 gene. The alignment of the protein sequence in different
species is shown below. The numeration of the amino acid residues corresponds to the mature COX6B1 as the first M is cleaved in the
import process of the precursor into mitochondria. The R19 residue and the conserved RFP motif are shown in red and yellow, respectively.1284 The American Journal of Human Genetics 82, 1281–1289, June 2008
of the R19 residue. The latter is part of a triplet R-F-P motif,
which has remained thoroughly invariant from yeast to
humans (Figure 2C).
Protein Modeling
Considering the crystal structure of bovine COX, the R19
residue is predicted to form a strong saline bond with the
adjacent highly conserved D17 residue and a weaker saline
bond with conserved D35 residue. These bonds help main-
tain the appropriate conformation of the COX6B1 N-
terminal loop, which is predicted to interact with subunit
2 of COX (Figure 2D). The substitution of an elongated,
ﬂexible R with a bulkier, shorter and rigid H residue may
well prevent the formation of the salt bridge with D35,
and weaken the salt bridge with D17, as well; this altered
conformation could in turn compromise the stability of
the COX6B1 subunit within the COX dimer, which is
the physiologically active form of the enzyme.
COX6B1 Knockdown Affects Human COX Activity
To investigate the role of the COX6B1 subunit on COX
function in a human system, we performed RNA interfer-
ence assays in HeLa cells. We used COX6B1sh1 and
COX6B1sh14, two shRNAs corresponding to speciﬁc
30 UTR sequences of the human COX6B1 transcript. A
real-time quantitative PCR assay showed that COX6B1
mRNA levels were decreased to 40% in both shRNA1 and
shRNA14 stably expressing cells compared to mock-trans-
fected cells (Figure 3A). Western-blot analysis showed
that COX6B1 protein levels were reduced to approximately
60% of controls (Figure 3C). Accordingly, the COX/CS ac-
tivities were signiﬁcantly reduced, to around 70%, in either
shRNA1- or shRNA14-versus mock-transfected HeLa cells
(p < 0.0026 and p < 0.0009 respectively, Figure 3B). There-
fore, reduced incorporation of COX6B1 determines the
formation of a functionally impaired enzyme.
Table 1. Respiratory-Chain-Complex Activities
Tissue and
Patient CI/CS CII/CS CIII/CS CIV/CS CV/CS CSa
Muscle
AK 17.8 24.3 136 37 238 155
AW 22.7 17.7 131 26 234 198
Normal 13.6–27.7 15–28 88–167 120–220 130–280 80–210
Fibroblasts
AK 29.2 15.3 107 52 117 119
AW 33.6 15.3 107 48 123 148
Normal 10.7–26 8.6–18.4 86–130 70–125 65–113 100–200
COX/CS values in the patients are in bold italic.
a CS, citrate synthase. Activity is expressed as nM/min/mg protein.The AmCytochrome C Oxidase Assembly in Patient Tissues
To test as whether the p.R19H mutation could affect
the stability of COX, we carried out WB analysis with
antibodies speciﬁc to several COX subunits. In experi-
ments based on denaturing, sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) on mutant
versus control muscle homogenate samples, we detected
reduced crossreacting material (CRM) for all tested
COX subunits, including COX6B1 (Figure 4A). To further
investigate the structural composition of mutant COX,
we analyzed the holocomplex from muscle homogenates
extracted in native conditions and separated by BNGE.
As shown in Figure 4A, fully assembled COX was re-
duced to approximately 40% in mutant versus control
muscle. Taken together, these results indicate that
the p.R19H change in COX6B1 compromises the stabil-
ity of the muscle COX holocomplex, thus reﬂecting
the severely reduced speciﬁc activity measured in this
tissue.
To test whether, and to what extent, the mutant
COX6B1R19H protein was incorporated into the holocom-
plex, we carried out BNGE-WB analysis in mitochondria
isolated from immortalized ﬁbroblasts, with antibodies
against several COX subunits. Incorporated MTCO1,
COX4, and COX5A CRMs were present in comparable
amounts in mutant versus control ﬁbroblast mitochon-
dria, whereas the amount of mutant COX6B1R19H
was substantially lower than that of COX6B1wild-type
(Figure 4B). In addition, the electrophoretic mobility of
the COX holocomplex was consistently altered in the mu-
tant samples (Figure 4B). When the same experiment was
carried out in denaturing conditions by SDS-PAGE WB
analysis, we detected no difference in the amount of any
COX-speciﬁc CRM, including that corresponding to
COX6B1, between mutant and control ﬁbroblast mito-
chondria. Taken together, these results suggest thatmutant
COX6B1R19H was normally expressed in ﬁbroblasts, but
failed to be, or to remain, stably incorporated in the COX
holocomplex. The functional relevance of the different
electrophoretic mobility of mutant COX holocomplex is
unclear, but it may suggest an altered conformation of its
quaternary structure.
Table 2. Cytochrome C Oxidase Activity, Normalized
by Citrate Synthase Activity in Control and Patient
Immortalized Fibroblasts
Sample COX/CSa
Control.pBabe 1005 19 (n ¼ 7)
A.K. pBabe 445 11b (n ¼ 9)
A.W. pBabe 505 19b (n ¼ 6)
a Expressed as % mean control value 5 standard deviation (SD).
b Student’s t test with respect to Control.pBabe: p < 0.0001.(D) Modeling of the bovine COX dimer. The COX6B1 and MT-CO2 subunits are in red/blue and yellow, respectively. The mutant R19 residue
and the adjacent D17 and D35 residues are also indicated. Relevant nitrogen atoms in R19 and oxygen atoms in D17 and D35 are shown in
blue and red, respectively (see main text for details).erican Journal of Human Genetics 82, 1281–1289, June 2008 1285
Figure 3. RNA Interference Assays in HeLa Cells
(A) Quantification by RT-PCR of the COX6B1 mRNA levels in the HeLa cells stable expression of the shRNAs corresponding to the sequences
number 1 and number 14 with respect to the mock-transfected cells (pSuper.puro) and the nontransfected HeLa cells.
(B) COX/CS activity measured in the HeLa cells stable expression of the shRNAs corresponding to sequences number 1 and number 14 with
respect to the mock-transfected cells (pSuper.puro) and the nontransfected HeLa cells. The plotted values are expressed as the percentage
of the mean value obtained for the nontransfected HeLa cells 5 SD (n ¼ 3).
(C) Western-blot analysis to determine the protein levels of the COX6B1 subunit and other COX subunits. The antibody against the SDH
30 kDa subunit (complex II) was used for normalization purposes.Complementation Studies in Yeast
Saccharomyces cerevisiae
In order to validate the pathogenic role of the human
COX6B1R19H mutant protein, we ﬁrst performed com-
plementation studies in BY4741Dcox12, a Saccharomyces
cerevisiae strain carrying a deletion of COX12, the yeast
COX6B1 gene ortholog. The Dcox12 strain does not respire
and fails to grow in obligatory aerobic media such as those
containing 2% ethanol (EtOH) as the only carbon source26
(see Figure 5A, pYEX strain). The Dcox12 strain was trans-
formed with either human COX6B1wild-type or mutant
human COX6B1R219H cDNAs. EtOH-dependent OXPHOS
growth of the Dcox12 strain was 35% slower, and oxygen
consumption was 25% lower in COX6B1R19H than in
COX6B1wild-type transformants (Figure 5A and Table 3).
Likewise, the activity of COX/CS in COX6B1R19H trans-1286 The American Journal of Human Genetics 82, 1281–1289, Juneformants was 67% to that of the COX6B1wild-type transform-
ants (Figure 5A and Table 3).
Complementation Studies in Human Cells
Transient or stable expression of recombinant
COX6B1wild-type andCOX6B1R19H cDNAs inHeLa cells failed
tomodify the COX activity relative to naive or mock-trans-
fected cells, thus excluding that expression of either re-
combinant construct could per se perturb the function of
the enzyme (Figure S2).
To establish the pathogenic role of the R19H mutation
in a human in vivo system, we stably expressed
COX6B1wild-type and COX6B1R19H cDNAs in immortalized
ﬁbroblasts derived from both patients. The stable expres-
sion of recombinant COX6B1wild-type was approximately
3-fold that of naive cells, whereas the stable expression of2008
COX6B1R19H was 5- to 6-fold, as conﬁrmed by RFLP densi-
tometry and real-time PCR analysis (Figure S3). Cytochem-
ical staining suggested the recovery of COX-speciﬁc reaction
in COX6B1wild-type-transfected mutant cells (Figure 5B). Ac-
cordingly, biochemical analysis showed a 50% increase
of COX activity in COX6B1wild-type-transfected cells, rela-
tive to mock-transfected cells, p < 0.0001 (Figure 5C),
whereas it remained unchanged in cells transfected with
mutant COX6B1R19H. In addition, BNGE-WB analysis
showed the appearance of a substantial amount of nor-
mally migrating COX holocomplex in COX6B1wild-type-
transfected mutant cells (Figure 5D). Taken together, these
results demonstrate that the p.R19H change is associated
with the functional and structural COX defect found in
our patients.
Discussion
We report here for the ﬁrst time that a mutation in a nu-
clear encoded COX subunit (COX6B1) causes a mitochon-
drial encephalomyopathy due to complex IV deﬁciency. In
addition to the genetic segregation of the mutant allele,
the absolute conservation of the R19 aminoacid residue,
and the in silico prediction of the structural consequences
of the R19H change, several functional data are consistent
with this mutation to be deleterious and highlight the role
of the COX6B subunit for the enzymatic activity of COX.
First, speciﬁc reduction of COX6B expression determines
a parallel reduction of COX activity in HeLa cells. Accord-
ingly, the genetic ablation of Cox12 in yeast leads to
severely defective respiration and aerobic growth and
marked reduction of the enzyme turnover, although no
apparent effect on activity26 results by detergent-based
removal of Cox12 from the holoenzyme. Second, rescue
Figure 4. Western-Blot Analysis of COX
Subunits
(A) Muscle homogenates. An antibody
against the SDH 30 kDa subunit (complex
II) was used for normalization. Assembled
complex IV holocomplex and individual
COX subunits are both decreased.
(B) Mitochondrial fractions from immortal-
ized fibroblasts (see text for details). Ar-
rows 1 and 2 indicate the band doublet cor-
responding to assembled COX species. S3
corresponds to a COX assembly intermedi-
ate.29–31
of the COX defect was obtained in
mutant cell lines expressing the
recombinant wild-type protein
(COX6B1wild-type), whereas the defect
was not corrected by expressing the
mutant species (COX6B1R19H). Third,
the DCOX12 yeast strain transformed
with the mutant human COX6B1 (hcox6b1R19H) showed
a signiﬁcantly lower growth rate, COX/CS, and respiration
activities, compared to the DCOX12 strain expressing
hcox6b1wild-type. Fourth, SDS-PAGE and BNGE-WB analyses
demonstrated that mutant COX6B1R19H failed to be or re-
main incorporated in the COX holoenzyme. As a conse-
quence, we observed a reduction of fully assembled COX
in muscle and the presence of an aberrant COX-related
band in ﬁbroblasts (band 2 in Figures 4B and 5D), possibly
due to altered quaternary structure of the mutant enzyme.
A faster migrating COX species was also reported in Barth’s
syndrome, a condition characterized by altered cardiolipin
composition of the mitochondrial inner membrane.27 In-
terestingly, cardiolipin is involved in the interaction of
COX6B1 with the COX holocomplex.28 Finally, our
BNGE-WB analyses clearly show that the S3 COX assembly
intermediate, also named subcomplex b,29,30 of control
samples did not contain COX6B1, which was present
in the fully assembled COX holocomplex (S4) (see
Figure 4B). This result suggests that, contrary to the current
view,31 COX6B1 is incorporated in the very last step of
COX assembly.
So far, only mutations of mtDNA encoded COX sub-
units or nucleus encoded COX assembly factors have
been associated with human COX deﬁciency,6,7,32 raising
the conjecture that mutations in nucleus encoded COX
structural subunits were not viable extra utero. However,
very recently, mutations that disrupt COX subunit 6A
and knockdown of subunit COX5A were reported in
Drosophila33 and zebraﬁsh,34 respectively. Both models
do not result in embryonic lethality but rather in neurode-
generation and COX deﬁciency. In agreement with these
experimental models, our own data show that disease-
causing abnormalities of nuclear COX subunits are also
possible in humans.The American Journal of Human Genetics 82, 1281–1289, June 2008 1287
Figure 5. Complementation Studies
(A) Growth of S. cerevisiae recombinant DCOX12 strains on 2% ethanol-YNB medium transfected with COX6B1R20H cDNA, COX6B1wild-type
cDNA, and the empty pYEX expression vector.
(B) Cytochemical reaction to COX in fibroblast cell lines.
(C) COX/CS activities, expressed as percentage of the mean control value5 SD, in immortalized fibroblasts and recombinant derivatives,
transfected as indicated (A.K. & A.W. pBabe þ pcDNA3: n ¼ 13; A.K. & A.W. pBabe þ COX6B1wild-type: n ¼ 15; A.K. & A.W. pBabe þ
COX6B1R19H: n ¼ 6).
(D) BNGE-WB analysis of COX in transfected cells. Gel gradient was 7%–10% for better separation of the COX holocomplex doublet (CIV 1
and CIV 2).Supplemental Data
Three ﬁgures are available at http://www.ajhg.org/.
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